Advertisement

Advertisement

2019 San Antonio Breast Cancer Symposium

Breast Cancer

Brief Highlights From the 2019 San Antonio Breast Cancer Symposium

In addition to our regular coverage of the 2019 San Antonio Breast Cancer Symposium, the following reports from the meeting include studies you may have missed. We hope you find them of interest. Ribo...

Breast Cancer

NSABP B-42 Trial 10-Year Update: Impact of Extended Letrozole on Disease-Free Survival

“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no signi...

Breast Cancer

Investigators in Brazil Explore Availability, Cost, and Use of Biosimilar Trastuzumab in Patients With HER2-Positive Breast Cancer

Investigators in Brazil are seeking to explore the efficacy and safety of adjuvant biosimilar trastuzumab in a real-world study of patients with early HER2-positive breast cancer. In 2019, biosimilar ...

Expert Point of View: Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, Assistant Professor of Medicine at Harvard Medical School and Associate Director of the Susan F. Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women’s Cancer C...

Immunotherapy
Breast Cancer

Small Study Explores Impact of Novel Regimen on Pembrolizumab for Triple-Negative Breast Cancer

In the phase II KEYNOTE-890 trial, patients with inoperable advanced triple-negative breast cancer who received one intratumoral tavokinogene telseplasmid injection followed by electroporation and pem...

Breast Cancer
Immunotherapy

Phase III SOPHIA Trial Evaluates Margetuximab/Chemotherapy vs Trastuzumab/Chemotherapy for HER2-Positive Breast Cancer

The second interim analysis of the phase III SOPHIA trial demonstrated a significant though modest improvement in progression-free survival, response rate, and clinical benefit with the addition of ma...

Immunotherapy
Breast Cancer

Phase III KEYNOTE-522: Pembrolizumab Benefits Outcome in Neoadjuvant, Adjuvant Settings in Triple-Negative Breast Cancer

In patients with triple-negative breast cancer, the addition of pembrolizumab to neoadjuvant and adjuvant chemotherapy achieves higher rates of pathologic complete response compared with placebo, acco...

Breast Cancer

Adding Capecitabine to Systemic Therapies Improves Outcomes in Triple-Negative Breast Cancer

Capecitabine improves disease-free and overall survival for patients with triple-negative breast cancer, but only when it is added to other systemic therapies, not when it is used as a substitute, acc...

Breast Cancer

Expert Point of View: A. Jo Chien, MD

A. Jo Chien, MD, Associate Professor at UCSF’s Helen Diller Comprehensive Cancer Center, San Francisco, was the formal discussant of this abstract. Dr. Chien said that a median follow-up of 3-years i...

Breast Cancer

Adjuvant Ado-Trastuzumab Emtansine vs Paclitaxel Plus Trastuzumab in Early HER2-Positive Breast Cancer

Results of the randomized, phase II ATEMPT trial showed that the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) failed to demonstrate improved safety when compared with paclitaxel plus tras...

Breast Cancer

Expert Point of View: Steven J. Isakoff, MD, PhD

Steven J. Isakoff, MD, PhD, a medical oncologist at Massachusetts General Hospital, Boston, commented on the results of the DESTINY-Breast01 trial. “These data are extraordinarily encouraging, sugges...

Breast Cancer

Phase II DESTINY-Breast01: T-DXd Effective in Pretreated, Metastatic HER2-Positive Breast Cancer

In heavily pretreated patients with HER2-positive metastatic breast cancer [fam-]trastuzumab deruxtecan-nxki (T-DXd), a novel antibody-drug conjugate, achieved high response rates and durable response...

Breast Cancer

Expert Point of View: Steven J. Isakoff, MD, PhD

“With longer follow-up, the addition of pertuzumab to chemotherapy and trastuzumab appears to show benefit in hormone receptor–­positive patients as well. In practice, we offer this regimen to node-po...

Breast Cancer

Chemotherapy, Trastuzumab, and Pertuzumab in Early HER2-Positive, Node-Positive Breast Cancer: Six-Year Follow-up of APHINITY Trial

Martine J. Piccart, MD, PhD, FASCO, reported that at 6-year follow-up of the APHINITY trial there was a modest, but not statistically significant, overall survival benefit for the addition of pertuzum...

Breast Cancer

Phase III HER2CLIMB Trial Yields Positive Data in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis

The investigational oral agent tucatinib added to trastuzumab/capecitabine reduced the risk of death by one-third and reduced the risk of disease progression or death by one-half in patients with heav...

Breast Cancer
Immunotherapy

Conference Highlights From the 2019 San Antonio Breast Cancer Symposium

More than 7,500 specialists in breast oncology from over 90 countries attended the 2019 San Antonio Breast Cancer Symposium (SABCS) held last December. Researchers convened to present a wide-ranging ...

Breast Cancer
Immunotherapy

Expert Point of View: Kevin Kalinsky, MD, MS

Commenting on SAFIR02-IMMUNO for The ASCO Post, Kevin Kalinsky, MD, MS, Associate Professor of Medicine at ­NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, said the findings o...

Breast Cancer
Immunotherapy

Mixed Results With Durvalumab Maintenance in HER2-Negative Advanced Breast Cancer

Given as maintenance therapy, the checkpoint inhibitor durvalumab significantly improved overall survival in patients with metastatic triple-negative breast cancer and yielded a numerical but not sign...

Breast Cancer
Immunotherapy

No Improved Pathologic Complete Response With Atezolizumab in Early Triple-Negative Breast Cancer

The addition of the checkpoint inhibitor atezolizumab to chemotherapy with carboplatin and nab-paclitaxel failed to significantly improve pathologic complete response rates compared with chemotherapy ...

Breast Cancer

Expert Point of View: Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, Assistant Professor of Medicine at Harvard Medical School and Associate Director of the Susan F. Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women’s Cancer C...

Breast Cancer

Triple-Negative Breast Cancer Responds to Novel Therapy

The phase II KEYNOTE-890 trial is a small but interesting study in patients with inoperable advanced triple-negative breast cancer. After one injection of intratumoral tavokinogene telseplasmid, a pla...

Breast Cancer
Immunotherapy

Neoadjuvant and Adjuvant Pembrolizumab Improves Pathologic Complete Response Rate in Triple-Negative Breast Cancer

The addition of pembrolizumab to neoadjuvant and adjuvant chemotherapy achieves higher rates of pathologic complete response compared with placebo in patients with triple-negative breast cancer, accor...

Breast Cancer

Expert Point of View: Harold J. Burstein, MD, PhD, FASCO

Commenting on Dr. DeMichele’s poster presentation at the 2019 San Antonio Breast Cancer Symposium, Harold J. Burstein, MD, PhD, FASCO, Professor of Medicine at Harvard Medical School and a medical on...

Breast Cancer

Real-World Use of Palbociclib and Abemaciclib Explored in Two Studies Based on Electronic Health Records Database

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are changing the landscape of the treatment of hormone receptor (HR)-positive/HER2-negative breast cancer. Three CDK4/6 inhibitors are approved by t...

Breast Cancer

When Added to Other Systemic Therapies, Capecitabine Improves Outcomes in Triple-Negative Breast Cancer

Capecitabine is often used to treat breast cancer, but the best use of capecitabine is open for discussion. According to a large meta-analysis of the effects of capecitabine in early breast cancer, ca...

Breast Cancer
Immunotherapy

Study Reports Similar Efficacy but No Less Toxicity With Adjuvant T-DM1 vs Taxane/Trastuzumab in Early Breast Cancer

The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) failed to show improved safety when compared with paclitaxel plus trastuzumab as adjuvant therapy in patients with stage 1 HER2-positive b...

Breast Cancer

Expert Point of View: Steven J. Isakoff, MD, PhD

“It is encouraging that the invasive disease–free survival observed in the primary analysis is holding up, particularly in the node-positive population. With longer follow-up, the addition of pertuzum...

Breast Cancer

APHINITY Update Supports Benefit of Pertuzumab-Based Triplet in Early HER2-Positive, Node-Positive Breast Cancer

Six-year follow-up of the APHINITY trial found a modest, but not statistically significant, overall survival benefit for the addition of pertuzumab to chemotherapy plus trastuzumab vs chemotherapy/tra...

Breast Cancer

Expert Point of View: Charles L. Shapiro, MD

Charles L. Shapiro, MD, Professor of Medicine, Hematology and Oncology at the Icahn School of Medicine at Mount Sinai, New York, commented on the Women’s Health Initiative update. “These trials invol...

Breast Cancer

Oral Paclitaxel Outperforms Intravenous Formulation in Phase III Trial

In the first reported phase III study of an oral taxane, an investigational oral form of paclitaxel yielded a higher overall response rate and produced less neuropathy than standard intravenous paclit...

Breast Cancer

Studies Find Estrogen Alone Protective, Estrogen Plus Progestin Detrimental in Postmenopausal Women

In postmenopausal women without prior breast cancer, estrogen alone reduced the risk of breast cancer, not only during treatment, but for years after estrogen was stopped. It also reduced deaths as a ...

Breast Cancer

Expert Point of View: Shelley Hwang, MD, MPH

Shelley Hwang, MD, MPH, the Mary and Deryl Hart Distinguished Professor of Surgery, Duke University School of Medicine in North Carolina, discussed the APBI IMRT Florence trial in a meeting highlight...

Breast Cancer

Partial-Breast Irradiation Favored Over Whole-Breast in Early Breast Cancer

Patients with early breast cancer with small, node-negative tumors can safely be treated with accelerated partial-breast irradiation using intensity-modulated radiotherapy. According to the 10-year me...

Breast Cancer

Expert Point of View: Debra A. Patt, MD, MPH, MBA, FASCO, and C. Kent Osborne, MD, FASCO

Debra A. Patt, MD, MPH, MBA, FASCO, Clinical Professor at Dell Medical School at The University of Texas at Austin and Executive Vice President of Public Policy and Strategy Initiatives for Texas Onc...

Breast Cancer

Breast Cancer Chemoprevention Effect Maintained Long After Stopping Anastrozole Therapy

For postmenopausal women at high risk for developing breast cancer—largely based on family history—anastrozole taken for 5 years maintained a preventive effect for at least an additional 7 years after...

Breast Cancer
Immunotherapy

Tucatinib Combination Extends Survival in HER2-Positive Metastatic Breast Cancer, Including Patients With Brain Metastases

For patients with progressing HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), no single regimen is an established standar...

Breast Cancer

Residual Cancer Burden Is Prognostic of Outcomes Across Breast Cancer Subtypes

Residual cancer burden after neoadjuvant chemotherapy can accurately predict disease recurrence and survival across all breast cancer subtypes, according to the findings from a meta-analysis presented...

Breast Cancer

Extended Letrozole Boosts Disease-Free Survival in 10-Year Update of NSABP B-42 Trial

“In the 10-year analysis of the NSABP B-42 trial, the effect of extended treatment with 5 years of letrozole on disease-free survival persisted and reached statistical significance. There was no signi...

Breast Cancer

Mixed Results With Weekly Nab-paclitaxel, Denosumab in Primary Breast Cancer

A weekly schedule of nab-paclitaxel as part of neoadjuvant chemotherapy significantly improved pathologic complete response compared with nab-paclitaxel given 2 weeks out of every 3 weeks (2/3) in pat...

breast cancer

Hope S. Rugo, MD, on Metastatic Triple-Negative Breast Cancer: Retrospective Analysis of PD-L1 Immunohistochemistry Assays

Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, discusses a retrospective analysis on the effectiveness of the VENTANA PD-L1 SP142 assay, the Dako 22C3 ass...

Breast Cancer

Expert Point of View: Steven J. Isakoff, MD, PhD

Steven J. Isakoff, MD, PhD, a medical oncologist at Massachusetts General Hospital, Boston, commented on the results of the DESTINY-Breast01 trial. “These data are extraordinarily encouraging, sugges...

Breast Cancer

Novel Antibody-Drug Conjugate Shows Efficacy in Women With Pretreated, Metastatic HER2-Positive Breast Cancer

The novel antibody-drug conjugate [fam-] trastuzu­mab deruxtecan (T-DXd) achieved high response rates and durable responses in heavily pretreated patients with HER2-positive metastatic breast cancer, ...

breast cancer

Terry P. Mamounas, MD, MPH, on Extending Letrozole Treatment in Hormone Receptor–Positive Breast Cancer

Terry P. Mamounas, MD, MPH, of Orlando Health UF Health Cancer Center, discusses 10-year results from NRG Oncology/NSABP B-42, which showed that, for postmenopausal women with hormone receptor–positiv...

breast cancer
immunotherapy

Luca Gianni, MD, on the Neoadjuvant Treatment of Triple-Negative Breast Cancer

Luca Gianni, MD, of the Fondazione Michelangelo, discusses findings from the NeoTRIP trial on pathologic complete response to neoadjuvant treatment with or without atezolizumab in triple-negative, ear...

breast cancer

Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer

Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurren...

breast cancer

Nadine M. Tung, MD, on HER2-Negative Breast Cancer: INFORM Trial of Cisplatin vs Doxorubicin/Cyclophosphamide

Nadine M. Tung, MD, of Beth Israel Deaconess Medical Center, discusses cisplatin vs doxorubicin/cyclophosphamide (AC) as neoadjuvant treatment in BRCA-mutation carriers with HER2-negative breast cance...

breast cancer

Ivana Sestak, PhD, on Clinical Treatment Score From TAILORx: Predicting Distant Breast Cancer Recurrence

Ivana Sestak, PhD, of Queen Mary University of London and the Centre for Cancer Prevention, discusses study findings that confirm the prognostic ability of the Clinical Treatment Score at 5 years (CTS...

breast cancer

Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD, on Omitting Breast Surgery: Results of the MICRA Trial

Marie-Jeanne T.F.D. Vrancken Peeters, MD, PhD, of the Netherlands Cancer Institute, discusses an interim study analysis showing that ultrasound-guided core biopsies of the breast in patients with exce...

breast cancer
immunotherapy

Ariella B. Hanker, PhD, on Therapeutic Implications of HER2 and HER3 Mutations in Breast Cancer

Ariella B. Hanker, PhD, of UT Southwestern Medical Center, discusses data showing that breast cancers expressing co-occurring HER2 and HER3 mutations may require the addition of a phosphoinositide 3-k...

breast cancer

Rowan T. Chlebowski, MD, PhD, on Breast Cancer: Findings From The Women’s Health Initiative

Rowan T. Chlebowski, MD, PhD, of the Lundquist Institute at Harbor-UCLA Medical Center, discusses the long-term influence of using estrogen plus progestin or estrogen alone on breast cancer incidence ...

Advertisement

Advertisement



Advertisement